RE:RE:RE:RE:RE:RE:RE:Price action "This company represents undervalued assets. There are 2 scenarios here. Gilles is trying hard to unlock shareholder value, or Gilles is not trying hard to unlock shareholder value. However, the end result remains the same."
Or Gilles has worked very hard and in addition to continuing records being set for the base business CZO's third pipeline asset may be about to enter human clinical trials in the summer. Not one. Not two. Three assets may have advanced to human clinical trials. Given preclinical risks that is exceptional and on top of the success of the base business which Symrise itself expects future value from. While the beta glucan pill suffered an unfortunate fate that's life and its pursuit led to PGX. CZO could go back to beta glucan in the future. It is not over for beta glucan; but CZO has other immediate priorities. Avenanthramide is the reason Gilles was originally attracted to CZO and a human clinical trial program has been approved. The avenanthramide pill may even benefit from a PGX carrier. There has been no data and no case made for the avenanthramide pill so Gilles efforts are not currently appreciated by the market. With an approved trial it is only a matter of time now. The fibrosis drug is before a trial decision in the summer and is basically an unkown to the market. The clinical case has not been made. Gilles has further added Ronnie Miller and a new CRO. The CRO is identifying new opportunities to expand and diversify the base business and has been working with Symrise to open new doors. A new VP of Technical Operations has been added, includng for product development as efforts to scale-up PGX enter a new phase. CZO also has the new oat flour/avenanthramide opportunity.
PGX development and other pipeline assets have suffered material unfortunate delays as labs were shutdown due to COVID. The unsuccessful outcome of the beta glucan pill affected CZO's development path along with the worst biotech market in history. Had the beta glucan pill been a success and the bear market had not happened CZO could have done a financing as originally anticipated and listed on NASDAQ. CZO is resilient and adjusted to the curcumstance. It has earned money with the base business, kept 100% of the upside for its pipeline assets and not sold out in Mickey Mouse deals, and has the cash to a number of opportunity defining catalysts. Ronnie Miller has endorsed CZO's strategic plan and CZO has also received significant and ongoing support from the government.
If instead of being overcome by the current price, which I believe is circumstantial, and focused on what 100% control of these assets could be worth in the next year with key data they could see this as an opportunity. Gilles has kept 100% of the upside, has continued to invest in the programs, the programs have never been stronger, and has the cash to the next opportunity defining milestones.